The 16 analysts offering 12-month price forecasts for Intercept Pharmaceuticals Inc have a median target of 25.50, with a high estimate of 82.00 and a low estimate of 11.00. The median estimate represents a +65.48% increase from the last price of 15.41.
The current consensus among 17 polled investment analysts is to Hold stock in Intercept Pharmaceuticals Inc. This rating has held steady since January, when it was unchanged from a Hold rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$1.04
Reporting Date Feb 24
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.